Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Aslan Presents Progress Update on its Three Clinical Candidates

publication date: Aug 13, 2019

Aslan Pharma of Singapore provided an update on the progress of its three clinical-stage oncology and immunology candidates:

• The company signed up K-MASTER to run a 400 patient South Korean Phase Ib/II trial of its lead drug, varlitinib, in patients with metastatic gastric cancer.
• ASLAN003 started a four-arm Phase II clinical trial for advanced relapsed/refractory acute myeloid leukemia;
• Aslan acquired global rights to ASLAN004 for all indications from CSL in a $780 million deal. Previously, Aslan had global rights only for asthma.

More details....

Stock Symbols: (NSDQ: ASLN, TPEx:6497)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.